KYOWA-KIRIN
On Friday, 12th April, 2024, Professor Julia Scarisbrick of University of Birmingham presented interim findings from the Kyowa Kirin, Inc. (Kyowa Kirin, TSA: 4151)-sponsored study, “Real-World Observational Study of Mogamulizumab in Adult Patients with Mycosis Fungoides and Sézary Syndrome (PROSPER)”, a prospective observational study evaluating the real-world impact of mogamulizumab on disease symptoms and health-related quality of life (HRQoL) in patients with these subtypes of cutaneous T-cell lymphoma (CTCL).
CTCL is a rare form of non-Hodgkin lymphoma that most prominently affects the skin, presenting as patches, plaques, tumours, or reddening of the entire skin, and may be associated with severe itching. In a proportion of cases, the disease may spread to the lymph nodes, blood, and/or other organs.
In the current interim analysis, symptom scores (mean) were reported for 20 adult patients with relapsed or refractory disease (8 MF; 12 SS) over their first 16 weeks of mogamulizumab treatment. Prior to treatment initiation, patients reported their symptom burden using a 1 – 10 numeric scale. At baseline, skin itch scored highest (6.6) followed by skin redness (6.2), flaking skin (5.9) and skin pain (4.0). Additionally, over half of patients reported having sleep problems either “frequently” or “every night” while 47% reported difficulties regulating body temperature “frequently” or “always”.
Improvement in all symptoms was reported within 4 weeks of treatment initiation and by week 16, symptom severity had decreased considerably with the greatest improvement seen in skin redness (-2.9) closely followed by skin itch (-2.7), flaking skin (-2.5) and skin pain (-2.2). Of note, the proportion of patients reporting sleep problems or difficulties regulating body temperature either “frequently” or “always” decreased to less than 20%.
“We know that CTCL patients not only suffer from the stress of a cancer diagnosis, but that these stresses are compounded by painful, red, scaly, and itchy lesions, tumours, and varying levels of discomfort,” says study principal investigator, Prof. Julia Scarisbrick of the University of Birmingham. “The PROSPER study is helping us understand these burdens better and the impact mogamulizumab may have on patients’ symptoms and quality of life.”
To view the full press release, click here.
KKI/INT/MOG/1081
Date of Preparation: April 2024
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240415169712/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NY-IFF1.5.2024 22:16:31 CEST | Press release
IFF Declares Dividend for Second Quarter 2024
CA-QUALCOMM-INCORPORATED1.5.2024 22:01:30 CEST | Press release
Qualcomm Earnings Release Available on Company’s Investor Relations Website
OCEANSIX-FUTURE-PATHS1.5.2024 20:25:29 CEST | Press release
Oceansix Announces Full-Year 2023 Financial Results
CA-LAMBDATEST1.5.2024 18:01:27 CEST | Press release
LambdaTest Enhances Security and Performance with SOCKS5 Proxy and HTTP/2 Support
GREENLAND-RESOURCES1.5.2024 17:08:36 CEST | Press release
Greenland Resources Provides Update
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom